1024 related articles for article (PubMed ID: 21835135)
21. Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis.
Straumann A; Hoesli S; Bussmann Ch; Stuck M; Perkins M; Collins LP; Payton M; Pettipher R; Hunter M; Steiner J; Simon HU
Allergy; 2013 Mar; 68(3):375-85. PubMed ID: 23379537
[TBL] [Abstract][Full Text] [Related]
22. A randomized, double-blinded, placebo-controlled study of the use of viscous oral cromolyn sodium for the treatment of eosinophilic esophagitis.
Lieberman JA; Zhang J; Whitworth J; Cavender C
Ann Allergy Asthma Immunol; 2018 May; 120(5):527-531. PubMed ID: 29544738
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of oral budesonide suspension in pediatric patients with eosinophilic esophagitis.
Gupta SK; Vitanza JM; Collins MH
Clin Gastroenterol Hepatol; 2015 Jan; 13(1):66-76.e3. PubMed ID: 24907502
[TBL] [Abstract][Full Text] [Related]
24. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.
Nair P; Pizzichini MM; Kjarsgaard M; Inman MD; Efthimiadis A; Pizzichini E; Hargreave FE; O'Byrne PM
N Engl J Med; 2009 Mar; 360(10):985-93. PubMed ID: 19264687
[TBL] [Abstract][Full Text] [Related]
25. Value of an Additional Review for Eosinophil Quantification in Esophageal Biopsies.
Stucke EM; Clarridge KE; Collins MH; Henderson CJ; Martin LJ; Rothenberg ME
J Pediatr Gastroenterol Nutr; 2015 Jul; 61(1):65-8. PubMed ID: 25633495
[TBL] [Abstract][Full Text] [Related]
26. Dietary therapy can reverse esophageal subepithelial fibrosis in patients with eosinophilic esophagitis: a historical cohort.
Lieberman JA; Morotti RA; Konstantinou GN; Yershov O; Chehade M
Allergy; 2012 Oct; 67(10):1299-307. PubMed ID: 22913672
[TBL] [Abstract][Full Text] [Related]
27. Serum eosinophil cationic protein is superior to mast cell tryptase as marker for response to topical corticosteroid therapy in eosinophilic esophagitis.
Schlag C; Pfefferkorn S; Brockow K; Haller B; Slotta-Huspenia J; Schulz S; von Werder A; Ring J; Schmid RM; Bajbouj M
J Clin Gastroenterol; 2014 Aug; 48(7):600-6. PubMed ID: 24177377
[TBL] [Abstract][Full Text] [Related]
28. Histopathologic variability in children with eosinophilic esophagitis.
Shah A; Kagalwalla AF; Gonsalves N; Melin-Aldana H; Li BU; Hirano I
Am J Gastroenterol; 2009 Mar; 104(3):716-21. PubMed ID: 19209168
[TBL] [Abstract][Full Text] [Related]
29. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway.
Flood-Page PT; Menzies-Gow AN; Kay AB; Robinson DS
Am J Respir Crit Care Med; 2003 Jan; 167(2):199-204. PubMed ID: 12406833
[TBL] [Abstract][Full Text] [Related]
30. Budesonide Oral Suspension Improves Symptomatic, Endoscopic, and Histologic Parameters Compared With Placebo in Patients With Eosinophilic Esophagitis.
Dellon ES; Katzka DA; Collins MH; Hamdani M; Gupta SK; Hirano I;
Gastroenterology; 2017 Mar; 152(4):776-786.e5. PubMed ID: 27889574
[TBL] [Abstract][Full Text] [Related]
31. Clinical presentation of patients with eosinophilic inflammation of the esophagus.
Baxi S; Gupta SK; Swigonski N; Fitzgerald JF
Gastrointest Endosc; 2006 Oct; 64(4):473-8. PubMed ID: 16996334
[TBL] [Abstract][Full Text] [Related]
32. Extracellular Eosinophil Granule Protein Deposition in Ringed Esophagus with Sparse Eosinophils.
Peterson KA; Cobell WJ; Clayton FC; Krishnamurthy C; Ying J; Pease LF; Saffari H; Georgelas A; Fang J; Gleich GJ; Leiferman KM
Dig Dis Sci; 2015 Sep; 60(9):2646-53. PubMed ID: 25902747
[TBL] [Abstract][Full Text] [Related]
33. Increased expression of eotaxin-3 distinguishes between eosinophilic esophagitis and gastroesophageal reflux disease.
Bhattacharya B; Carlsten J; Sabo E; Kethu S; Meitner P; Tavares R; Jakate S; Mangray S; Aswad B; Resnick MB
Hum Pathol; 2007 Dec; 38(12):1744-53. PubMed ID: 17900656
[TBL] [Abstract][Full Text] [Related]
34. Optimal Biopsy Protocol to Evaluate Histological Effectiveness of Proton Pump Inhibitor Therapy in Patients with Eosinophilic Esophagitis.
Fujiwara Y; Hashimoto A; Uemura R; Sawada A; Otani K; Tanaka F; Yamagami H; Tanigawa T; Watanabe T; Kabata D; Kuwae Y; Shintani A; Ohsawa M
Digestion; 2019; 100(1):64-71. PubMed ID: 30408792
[TBL] [Abstract][Full Text] [Related]
35. Eosinophilic peak counts in eosinophilic esophagitis : a retrospective study.
Vanstapel A; Vanuytsel T; De Hertogh G
Acta Gastroenterol Belg; 2019; 82(2):243-250. PubMed ID: 31314183
[TBL] [Abstract][Full Text] [Related]
36. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis.
Oldhoff JM; Darsow U; Werfel T; Katzer K; Wulf A; Laifaoui J; Hijnen DJ; Plötz S; Knol EF; Kapp A; Bruijnzeel-Koomen CA; Ring J; de Bruin-Weller MS
Allergy; 2005 May; 60(5):693-6. PubMed ID: 15813818
[TBL] [Abstract][Full Text] [Related]
37. Childhood esophagitis: then and now.
Lee JJ; Baker RD; Khan AR; Baker SS
J Pediatr Gastroenterol Nutr; 2009 Jan; 48(1):37-40. PubMed ID: 19172121
[TBL] [Abstract][Full Text] [Related]
38. Predictors of histologic response to mepolizumab in pediatric eosinophilic esophagitis.
Wong ECL; Gleave AL; Marshall JK; Narula N
Eur J Gastroenterol Hepatol; 2023 Oct; 35(10):1131-1136. PubMed ID: 37577798
[TBL] [Abstract][Full Text] [Related]
39. No effect of anti-interleukin-5 therapy (mepolizumab) on the atopy patch test in atopic dermatitis patients.
Oldhoff JM; Darsow U; Werfel T; Bihari IC; Katzer K; Laifaoui J; Plötz S; Kapp A; Knol EF; Bruijnzeel-Koomen CA; Ring J; de Bruin-Weller MS
Int Arch Allergy Immunol; 2006; 141(3):290-4. PubMed ID: 16931891
[TBL] [Abstract][Full Text] [Related]
40. Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis.
Straumann A; Conus S; Degen L; Frei C; Bussmann C; Beglinger C; Schoepfer A; Simon HU
Clin Gastroenterol Hepatol; 2011 May; 9(5):400-9.e1. PubMed ID: 21277394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
